U.S. markets closed
  • S&P 500

    3,693.23
    -64.76 (-1.72%)
     
  • Dow 30

    29,590.41
    -486.27 (-1.62%)
     
  • Nasdaq

    10,867.93
    -198.88 (-1.80%)
     
  • Russell 2000

    1,679.59
    -42.72 (-2.48%)
     
  • Crude Oil

    79.43
    -4.06 (-4.86%)
     
  • Gold

    1,651.70
    -29.40 (-1.75%)
     
  • Silver

    18.83
    -0.78 (-3.99%)
     
  • EUR/USD

    0.9693
    -0.0145 (-1.47%)
     
  • 10-Yr Bond

    3.6970
    -0.0110 (-0.30%)
     
  • GBP/USD

    1.0857
    -0.0398 (-3.54%)
     
  • USD/JPY

    143.3300
    +0.9950 (+0.70%)
     
  • BTC-USD

    18,989.53
    -67.42 (-0.35%)
     
  • CMC Crypto 200

    434.61
    -9.92 (-2.23%)
     
  • FTSE 100

    7,018.60
    -140.92 (-1.97%)
     
  • Nikkei 225

    27,153.83
    -159.30 (-0.58%)
     

Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings

·1 min read
  • Theravance Biopharma Inc (NASDAQ: TBPH) is buying back over 9.6 million shares from GSK plc (NYSE: GSK) for roughly $94 million, according to an SEC filing.

  • In addition, Theravance plans to buy back $95 million from its existing investors "in the near term" and another $60 million in its shares on the open market.

  • In a press release, Theravance says it hopes to complete that part of its plan by the end of 2023.

  • Related content: Theravance Biopharma's Ampreloxetine Shows Benefit In Atrophy Patients, But Not In Parkinson's.

  • The move is the latest in a back-and-forth between GSK, Theravance, and Theravance's spinoff Innoviva, Inc. (NASDAQ: INVA).

  • In May 2021, GSK offloaded its stake in Innoviva with 32 million shares at $12.25 per share, raising gross proceeds of approximately $392 million.

  • In July, Theravance and Innoviva sold their royalty rights to GSK's Trelegy to Royalty Pharma (NASDAQ: RPRX) for an upfront $1.3 billion.

  • Price Action: TBPH shares are up 2.48% at $10.32 on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.